RP
REGN icon

Rowlandmiller & Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Rowlandmiller & Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-116
Closed -$122K – 189
2024
Q3 		$122K Hold
116
– – 0.02% 168
2024
Q2 		$122K Hold
116
– – 0.03% 161
2024
Q1 		$112K Hold
116
– – 0.02% 175
2023
Q4 		$102K Buy
+116
New +$95.5K 0.02% 177
2023
Q2 		– Sell
-171
Closed -$141K – 185
2023
Q1 		$141K Buy
+171
New +$129K 0.03% 155

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rowlandmiller & Partners's REGN Position: Q4 2024 in Review

Rowlandmiller & Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 116 shares — an estimated $122K sold.

Rowlandmiller & Partners first reported a position in REGN in Q1 2023 and held it in 5 quarters. The position peaked at $141K in Q1 2023. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Rowlandmiller & Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Rowlandmiller & Partners sold 116 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $122K.
  • Rowlandmiller & Partners first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • Rowlandmiller & Partners's Regeneron Pharmaceuticals position peaked at $141K in Q1 2023.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Rowlandmiller & Partners's 13F filing for Q4 2024, filed 4 Feb 2025.